Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:51:32.691Z.
Calculation as of: 2026-10-06T15:51:32.691Z.
Quote observation: 2026-10-06T15:50:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e02887d9f7d553dead588493e3d1cc1cda6164751857f77264c258b40fe63259
PE RATIO
N/A
Market Cap
$290.91M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$269.13M
PE Ratio
N/A
TTM Avg
15.73
3Y Avg
15.73
5Y Avg
15.86
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | $283.92M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $283.42M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $280.60M | N/A | 46.08 | 46.08 | 46.08 |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.87M | N/A | 6.29 | 6.29 | 6.29 |
| Fate Therapeutics, Inc. (FATE)vs › | $279.16M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $290.91M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $290.74M | N/A | N/A | N/A | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $276.26M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $269.13M | N/A | 15.73 | 15.73 | 15.86 |
| Larimar Therapeutics, Inc. (LRMR)vs › | $297.62M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$3.72
Forward EPS (Est.)
$-0.60
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
